pharmaphorum
MARCH 29, 2022
With the rapid onset of the pandemic, the race to develop a viable vaccine quickly became a race to secure access to the developed vaccines. In this article, Ben Hargreaves examines how wealth determined the winners and what is now underway to help lower-income countries gain access to the available vaccines.
pharmaphorum
OCTOBER 17, 2022
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of Takeda GmbH’s live, attenuated dengue tetravalent vaccine, Qdenga ( TAK-003 ). Medicines submitted under EU-M4all are assessed by the CHMP in collaboration with the WHO and target countries.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
FEBRUARY 26, 2024
At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines.
European Pharmaceutical Review
SEPTEMBER 21, 2022
Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. Adapted vaccines Comirnaty Original/Omicron BA.1 Adapted vaccines Comirnaty Original/Omicron BA.1
European Pharmaceutical Review
NOVEMBER 14, 2022
Four medicines recommended for approval in the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP)’s latest meeting included a biosimilar for osteoporosis and a novel COVID-19 vaccine. COVID-19 update. 5 in children five to 11 years. CHMP’s safety update.
European Pharmaceutical Review
APRIL 3, 2023
It is the eighth vaccine recommended in the European Union (EU) for COVID-19. The committee adopted a positive opinion for Briumvi (ublituximab) for relapsing multiple sclerosis (MS). It relies partly on results of pre-clinical tests and clinical trials of an already authorised reference product and in part on new data.
pharmaphorum
DECEMBER 15, 2020
“Now more than ever, it is our responsibility as a sector to ensure affordable access to healthcare and enable the future longevity of medicine development and supply.”. The generics medicines sector can, too, play a substantial part in discovering new areas for licensed products to be used in. Delivery of essential medicines.
Expert insights. Personalized for you.
88 
Let's personalize your content